Ranibizumab combined with photodynamic therapy for the treatment of advanced-stage exudative age-related macular degeneration: study protocol for a self-controlled trial and preliminary results

doi:10.3969/j.issn.2095-4344.0263

Abstract

Abstract:

BACKGROUND: The lack of visual field in the visual center of older adults with aged-related macular degeneration (AMD) will have a serious impact on the activities of daily living. There are atrophic and exudative AMD according to the pathological manifestations. Patients with advanced stage of exudative AMD will develop aged-related degeneration in the macular area. Ranibizumab combined with photodynamic therapy is mainly used for current treatment of exudative AMD, but more attention is paid to patients with early exudative AMD.
OBJECTIVE: To analyze vision recovery, retinal thickness, and leakage of choroidal neovascular lesions in patients with advanced stage of exudative AMD after treatment with ranibizumab plus photodynamic therapy, and further explore the therapeutic efficacy of the combined therapy.
METHODS: The prospective self-controlled trial will be completed in the Department of Ophthalmology, Affiliated Hospital of Qinghai University in China. The study population will comprise 113 patients with advanced exudative AMD who are eligible for inclusion and exclusion criteria. Photodynamic therapy combined with intravitreal injection of ranibizumab will be given as the interventional therapy.
RESULTS AND CONCLUSION: The primary outcome measure of the trial is to investigate the visual improvement in patients 12 months after treatment. Secondary outcome measures include logarithmic visual acuity chart scores, retinal thickness, and leakage of choroidal neovascular lesions assessed monthly at 1-12 months after treatment, and adverse events during follow-up. Preliminary results showed that at 12 months after treatment, visual acuity in 43 affected eyes was increased by ≥ 2 lines, and the average retinal thickness decreased by 111.21 μm as compared with before treatment. Leakage of choroidal neovascular lesions in most affected eyes stopped or the lesions were contracted. Findings from the trial are expected to provide reliable data on the efficacy of ranibizumab combined with photodynamic therapy in the treatment of advanced exudative AMD, thereby providing a basis for the rational use of this combined therapy in the treatment of advanced exudative AMD. This trial was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR1800015410). Protocol version (1.0).

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Macular Degeneration, Photochemotherapy, Tissue Engineering

CLC Number:

R318

Yu Ping, Wang Qing, Liu Ling-ling. Ranibizumab combined with photodynamic therapy for the treatment of advanced-stage exudative age-related macular degeneration: study protocol for a self-controlled trial and preliminary results[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(16): 2588-2592.

Figures/Tables 1

References

[1] Gbd 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053): 1545-1602.

[2] Singh N, Srinivasan S, Muralidharan V, et al. Prevention of Age-Related Macular Degeneration. Asia Pac J Ophthalmol (Phila). 2017;6(6):520-526.

[3] Liu JJ, Liu ZY, Peng Q. Recent advances in anti-vascular endothelial growth factor for exudative age-related macular degeneration. Yanke Xinjinzhan. 2015;35(1):84-88.

[4] 中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制订委员会. 中国老年性黄斑变性临床诊断治疗路径[J]. 中华眼底病杂志,2013,29(4):343-355.

[5] Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267.

[6] Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014(9): Cd011230.

[7] Virgili G, Michelessi M, Parodi MB, et al. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev. 2015; (10):CD006537.

[8] Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2007(3):CD004763.

[9] Nakai S, Honda S, Matsumiya W, et al. ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration. Mol Vis. 2017;23:514-519.

[10] Hatz K, Schneider U, Henrich PB, et al. Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration: 12 months of retreatment and vision outcomes from a randomized study. Ophthalmologica. 2015; 233(2):66-73.

[11] Krebs I, Vecsei Marlovits V, Bodenstorfer J, et al. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Acta Ophthalmol. 2013; 91(3):e178-183.

[12] Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145(5):862-874.

[13] Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol. 2003;121(9):1253-1268.

[14] Niu TR. The 5-grade notation of the standard logarithmic visual acuity chart. Yan Shiguang Xue Zazhi. 2005;7(4): 217-219.

[15] Wu MX, Zheng Z, Zhou XY. New research progress on the epidemiology of age - related macular degeneration. Guoji Yanke Zazhi. 2015;15(2):223-227.

[16] Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385(9967):509-516.